![Yoshihiko Futamura](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yoshihiko Futamura active positions
Companies | Position | Start | End |
---|---|---|---|
Hinge Therapeutics, Inc.
![]() Hinge Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Hinge Therapeutics, Inc. is an early-stage biopharmaceutical company based in Torrance, CA. The private company focuses on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs. The company's proprietary technology, the Hinge drug discovery platform, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA. The current areas of interest include bleeding disorders, solid tumors, cardiovascular diseases, CNS, rare disease, and anti-aging. Hinge Therapeutics is seeking investors/partners who can help them advance their programs while further establishing their "Hinge drug discovery platform" which can be applied to many other challenging targets. The company was founded by Yoshihiko Futamura, and the CEO is Akiko Futamura. | Director/Board Member | - | - |
Founder | - | - |
Career history of Yoshihiko Futamura
Statistics
International
United States | 2 |
Operational
Director/Board Member | 1 |
Founder | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Hinge Therapeutics, Inc.
![]() Hinge Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Hinge Therapeutics, Inc. is an early-stage biopharmaceutical company based in Torrance, CA. The private company focuses on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs. The company's proprietary technology, the Hinge drug discovery platform, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA. The current areas of interest include bleeding disorders, solid tumors, cardiovascular diseases, CNS, rare disease, and anti-aging. Hinge Therapeutics is seeking investors/partners who can help them advance their programs while further establishing their "Hinge drug discovery platform" which can be applied to many other challenging targets. The company was founded by Yoshihiko Futamura, and the CEO is Akiko Futamura. | Health Technology |
- Stock Market
- Insiders
- Yoshihiko Futamura
- Experience